Hear an expert overview of emerging options for prevention and outpatient treatment of COVID-19, and learn the rationale for increased federal investment into developing oral antivirals against SARS-CoV-2.
Review compelling new data on the use of monoclonal antibodies as postexposure prophylaxis for persons exposed to SARS-Cov-2 and as outpatient therapy and inpatient therapy for persons with COVID-19.
Join Arthur Kim, MD, as he discusses exciting data supporting the implementation of oral and IV antiviral medications for postexposure prophylaxis and treatment of SARS-CoV-2.
Join Michael G. Ison, MD, MS, as he reviews the latest recommendations and data supporting currently available outpatient treatment options for COVID-19 and provides a roadmap for implementation of the different strategies.
Here’s why we must target our recommendations to treat patients using agents with strong supporting data.
Expert review of the rationale, clinical data, and treatment recommendations supporting timeliness in the administration of therapies that act directly against SARS-CoV-2.
Gain expert insights on the optimal therapeutic approach for each stage of COVID-19 disease and the guideline recommendations that support timeliness of treatment.
Hear expert insights on therapies under evaluation or authorized for the treatment of patients with COVID-19, including which antivirals to use and when, and how to operationalize administration of anti–SARS-CoV-2 monoclonal antibodies in the outpatient setting.